Compare · COYA vs NVO
COYA vs NVO
Side-by-side comparison of Coya Therapeutics Inc. (COYA) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both COYA and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $173.66B, about 1705.8x COYA ($101.8M).
- Over the past year, COYA is down 33.2% and NVO is down 30.4% - NVO leads by 2.9 points.
- COYA has been more active in the news (5 items in the past 4 weeks vs 3 for NVO).
- NVO has more recent analyst coverage (25 ratings vs 3 for COYA).
- Company
- Coya Therapeutics Inc.
- Novo Nordisk A/S
- Price
- -
- -
- Market cap
- $101.8M
- $173.66B
- 1M return
- -9.70%
- -10.14%
- 1Y return
- -33.23%
- -30.36%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2022
- News (4w)
- 5
- 3
- Recent ratings
- 3
- 25
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest COYA
- SEC Form 8-K filed by Coya Therapeutics Inc.
- Coya to Initiate Open-Label Extension of Phase 2/3 ALSTARS Trial of COYA 302 in ALS
- Coya Therapeutics Announces Participation at Chardan's 10th Annual Healthcare Conference
- SEC Form 8-K filed by Coya Therapeutics Inc.
- Coya Therapeutics Announces Completion of Full Enrollment in Phase 2/3 ALSTARS Trial of COYA 302 for the Treatment of ALS
- SEC Form 8-K filed by Coya Therapeutics Inc.
- Coya Therapeutics Announces Enrollment of 100th Participant in Phase 2/3 ALSTARS Trial of COYA 302 for the Treatment of ALS
- Coya Therapeutics Announces Publication of Preclinical Study Demonstrating Combination Immunomodulatory Effects of COYA 303 in a Well-Established Model of Peripheral and CNS Inflammation
- SEC Form 10-Q filed by Coya Therapeutics Inc.
- Coya Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo Nordisk A/S downgraded by Morgan Stanley with a new price target
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo Nordisk A/S downgraded by Deutsche Bank